Because EGFR inhibition can downregulate HIF-1α expression in tumor cells and decrease VEGF secretion, we hypothesized that erlotinib treatment would indirectly lead to vascular normalization and decrease tumor hypoxia. Here, EGFR is linked to neoplasm.